Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Everolimus in refractory testicular germ cell cancer
2011-001502-10Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in germ cell tumor (GCT), sponsored by National Cancer Institute. Primary endpoint: Response rate per RECIST v1.1. Started Oct 2011; status: completed.
02
Drugs
everolimus
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2011-001502-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001502-10.